These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1481607)

  • 1. [The safety of a new chemical typhoid preparation containing a complex of Vi and K antigens in tests of its acute and chronic toxicity].
    Kharitonova AM; Grigor'eva LV; Bykovskaia SI; Ageeva VA; Stepanova LK; Belaia IuA
    Zh Mikrobiol Epidemiol Immunobiol; 1992; (9-10):57-60. PubMed ID: 1481607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A chemical typhoid vaccine containing a surface-antigen complex including the K-antigen].
    Stepanova LK; Belaia IuA; Sergeeva NS; Ageeva VA; Petrukhin VG
    Zh Mikrobiol Epidemiol Immunobiol; 1993; (1):51-6. PubMed ID: 7520650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vi antigen from Salmonella typhosa and immunity against typhoid fever. I. Isolation and immunologic properties in animals.
    Wong KH; Feeley JC; Northrup RS; Forlines ME
    Infect Immun; 1974 Feb; 9(2):348-53. PubMed ID: 4205947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Production of a complex chemical typhoid vaccine containing O-, Vi, and H-antigens].
    Gekker VD; Sergeeva NS
    Zh Mikrobiol Epidemiol Immunobiol; 1973 Jan; 50(1):14-8. PubMed ID: 4780106
    [No Abstract]   [Full Text] [Related]  

  • 5. Adhesion of Vi antigen and toxicity in typhoid vaccines inactivated by acetone or by heat and phenol.
    Wong KH; Feeley JC; Pittman M; Forlines ME
    J Infect Dis; 1974 May; 129(5):501-6. PubMed ID: 4207306
    [No Abstract]   [Full Text] [Related]  

  • 6. [Immunochemical study of the antigenic complexes from typhoid-paratyphoid A and B bacteria obtained industrially].
    Khatuntseva NV; Mironova MV; Riapolova RG; Rybasova GV
    Zh Mikrobiol Epidemiol Immunobiol; 1974 Jun; 51(6):50-5. PubMed ID: 4409774
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of purified Vi polysaccharide typhoid vaccine.
    Park JH; Hong JJ; Choi ES; Lee JW; Park JH
    J Vet Sci; 2002 Jun; 3(2):67-70. PubMed ID: 12441674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
    Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
    Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Toxic and allergic properties of associated vaccines].
    Gapochko KG; Saltykova TA; Strukova LM
    Voen Med Zh; 1977 Nov; (11):61-3. PubMed ID: 595444
    [No Abstract]   [Full Text] [Related]  

  • 10. Purified Vi antigens as possible typhoid vaccines.
    Pistole TG; Marcus S
    Immunol Commun; 1974; 3(3):227-38. PubMed ID: 4606971
    [No Abstract]   [Full Text] [Related]  

  • 11. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi.
    Robbins JD; Robbins JB
    J Infect Dis; 1984 Sep; 150(3):436-49. PubMed ID: 6207249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The toxic and immunomodulating properties of the somatic O-antigen polysaccharide of typhoid bacteria].
    Duplishcheva AP; Sinilova NG; Kharitonova AM; Bykovskaia SI; Grigor'eva LV; Snegireva AE; Shaposhnikova GV; Andreeva IV; Rusina OIu
    Farmakol Toksikol; 1991; 54(1):40-3. PubMed ID: 1713560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever.
    Tacket CO; Levine MM; Robbins JB
    Vaccine; 1988 Aug; 6(4):307-8. PubMed ID: 3188615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunochemical examination of typhoid and paratyphoid vaccines prepared from envelope and O antigens (author's transl)].
    Hatunceva NV; Mironova MV; Ryapolova RG
    Acta Microbiol Acad Sci Hung; 1974; 21(1-2):135-41. PubMed ID: 4216248
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of a Vi-degrading enzyme on potency of typhoid vaccines in mice.
    Wong KH; Feeley JC; Pittman M
    J Infect Dis; 1972 Apr; 125(4):360-6. PubMed ID: 4553079
    [No Abstract]   [Full Text] [Related]  

  • 16. [Comparison of oral and subcutaneous immunization against typhoid-paratyphoid fever (author's transl)].
    Krasnoproshina LI
    Acta Microbiol Acad Sci Hung; 1974; 21(1-2):151-60. PubMed ID: 4216249
    [No Abstract]   [Full Text] [Related]  

  • 17. Vi Capsular Polysaccharide Produced by Recombinant
    Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
    Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection in a mouse peritonitis model mediated by iron-regulated outer-membrane protein of Salmonella typhi coupled to its Vi antigen.
    Chibber S; Bhardwaj SB
    J Med Microbiol; 2004 Jul; 53(Pt 7):705-709. PubMed ID: 15184544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunological paralysis. V. The histological changes in the organs of mice following the administration of massive doses of typhoid Vi-antigen].
    Levenson VI; Durnova GN; Kaplanekiĭ AS
    Zh Mikrobiol Epidemiol Immunobiol; 1974 Sep; (9):60-4. PubMed ID: 4440338
    [No Abstract]   [Full Text] [Related]  

  • 20. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
    Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
    Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.